drugset / Trial / NCT00484003

A Quality of Life and Safety Study With Pimecrolimus Cream, 1% in Children (Age 2-12 Years) With Atopic Dermatitis

NCT00484003

Phase 4 Completed Novartis
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The study will evaluate the safety and effect of pimecrolimus cream 1% on quality of life of caregivers of South African children with mild to moderate atopic dermatitis (AD).

Timeline

Start
2004-10
Primary completion
Completion
2004-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Pimecrolimus Small molecule 1 %

Indications